

# Depression in chronically ill elderly

<b>Submission date</b> 12/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 12/09/2005	<b>Overall study status</b> Completed	<input checked="" type="checkbox"/> Protocol
<b>Last Edited</b> 01/05/2012	<b>Condition category</b> Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof J Th M van Eijk

**Contact details**  
Universiteit Maastricht  
Faculty of Health Sciences  
Department of Health Care Studies  
Section Medical Sociology  
P.O. Box 616  
Maastricht  
Netherlands  
6200 MD  
+31 (0)43 3882283  
j.vaneijk@zw.unimaas.nl

## Additional identifiers

**Protocol serial number**  
ZONMW registration number: 945-03-047; NTR70

## Study information

**Scientific Title**

**Acronym**

DELTA (Depression in Elderly with Long-Term Afflictions)

**Study objectives**

Minimal psychological intervention (MPI) will reduce levels of depression and will increase their quality of life, while reducing health care-related costs in chronically ill elderly people with a depressed mood.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised open label active controlled parallel group trial

**Primary study design**

Interventional

**Study type(s)**

Prevention

**Health condition(s) or problem(s) studied**

Depression

**Interventions**

Minimal psychological intervention (MPI) versus care as usual.

**Intervention Type**

Other

**Phase**

Not Specified

**Primary outcome(s)**

1. Beck Depression Inventory (BDI) assessed at baseline and at 3, 6 and 12 months after inclusion
2. Cost-effectiveness and cost-utility assessed using cost-diaries
3. EuroQol at baseline and at 3, 6, 9 and 12 months after inclusion

**Key secondary outcome(s)**

1. Quality of life (SF-36) assessed at baseline and at 3, 6 and 12 months after inclusion
2. Daily functioning
3. Self-efficacy
4. Autonomy
5. Participation

**Completion date**

15/11/2006

# Eligibility

## Key inclusion criteria

1. Established diagnosis of Diabetes Mellitus Type II or chronic obstructive pulmonary disease (COPD)
2. Age 60 years and over
3. Community dwelling
4. Minor depression or mild and moderate categories of major depression according to MINI and Hamilton-criteria (DSM-IV)
5. Completed informed consent.

## Participant type(s)

Patient

## Healthy volunteers allowed

No

## Age group

Senior

## Sex

All

## Key exclusion criteria

1. Treatment with antidepressants
2. Major depression
3. Major psychiatric problems
4. Current psychosocial/psychiatric treatment
5. Serious cognitive problems (demential syndrome)
6. On waiting list for nursing home
7. Bedridden
8. Recent loss of spouse (<3 months)
9. Non Dutch-speaking

## Date of first enrolment

15/07/2003

## Date of final enrolment

15/11/2006

# Locations

## Countries of recruitment

Netherlands

## Study participating centre

Universiteit Maastricht

Maastricht

Netherlands  
6200 MD

## Sponsor information

### Organisation

University Maastricht (The Netherlands)

### ROR

<https://ror.org/02jz4aj89>

## Funder(s)

### Funder type

Government

### Funder Name

The Netherlands Organization for Health Research and Development (ZonMw) (Netherlands)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/10/2009		Yes	No
<a href="#">Results article</a>	results	01/12/2010		Yes	No
<a href="#">Results article</a>	results	01/02/2012		Yes	No
<a href="#">Protocol article</a>	protocol	21/06/2006		Yes	No